• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·BAYERCROP.NS
Share

Bayer CropScience Limited Stocks

₹ 4077Last Updated 14.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

₹ 1.95B

₹ 4077
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bayer CropScience Limited, founded in Thane, India, in 1958, is a diversified enterprise involved in various sectors, including agriculture, pharmaceuticals, and consumer health, with a global reach encompassing India, Germany, and Bangladesh, among other international markets. The company's agricultural segment is dedicated to the manufacturing, sales, and distribution of an extensive array of crop protection products, such as insecticides, fungicides, and herbicides, alongside other specialized agrochemicals. It also provides hybrid seeds, including corn and paddy varieties, to agriculturalists. In the pharmaceutical domain, Bayer CropScience delivers medicines primarily targeting cardiology, gynecology, diabetes, oncology, and ophthalmology. Additionally, it supplies advanced diagnostic imaging technologies, such as computed tomography (CT), X-ray, and magnetic resonance imaging (MRI) equipment, together with essential contrast agents. Its consumer health division offers a selection of products designed for daily wellness and the management of minor ailments. Pioneering digital solutions for farming, the company provides platforms like FarmRiseTM and other predictive systems. These tools integrate and analyze vast amounts of data from sources such as farm machinery, satellites, field sensors, irrigation networks, and drones. Leveraging data science and sophisticated predictive analytics, these systems furnish farmers with actionable insights to optimize their decision-making. The company also actively exports its comprehensive range of products.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of BAYERCROP.NS is 5130 and suggests 25.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 20:45

"She has more lives than a cat": An investor from *The Short Game* on IBM's collapse

15.07.2026 20:22

Morgan Stanley's profits soared thanks to SpaceX's IPO and revenue from stock trading

15.07.2026 19:54

Sales at Cartier's parent company were twice as strong as expected. This bolstered the luxury market

15.07.2026 19:06

Oppenheimer withdrew its recommendation to buy IBM stock following its historic plunge

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026